TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis

PurposeIt has been reported that PI3K/AKT pathway is altered in various cancers and AKT isoforms specifically regulate cell growth and metastasis of cancer cells; AKT1, but not AKT2, reduces invasion of cancer cells but maintains cancer growth. We propose here a novel mechanism of the tumor suppresser, TIS21/BTG2, that inhibits both growth and invasion of triple negative breast cancer cells via AKT1 activation by differential regulation of mTORc1 and mTORc2 activity.MethodsTransduction of adenovirus carrying TIS21/BTG2 gene and transfection of short interfering RNAs were employed to regulate TIS21/BTG2 gene expression in various cell lines. Treatment of mTOR inhibitors and mTOR kinase assays can evaluate the role of mTORc in the regulation of AKT phosphorylation at S473 residue by TIS21/BTG2 in breast cancer cells. Open data and immunohistochemical analysis were performed to confirm the role of TIS21/BTG2 expression in various human breast cancer tissues.ResultsWe observed that TIS21/BTG2 inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregulation of tsc1 expression, which lead to significant reduction of p70S6K activation as opposed to AKT1S473, but not AKT2, phosphorylation via downregulating PHLPP2 (AKT1-specific phosphatase) in breast cancers. TIS21/BTG2-induced pAKTS473 required Rictor-bound mTOR kinase, indicating activation of mTORc2 by TIS21/BTG2 gene. Additionally, the TIS21/BTG2-induced pAKTS473 could reduce expression of NFAT1 (nuclear factor of activated T cells) and its target genes, which regulate cancer microenvironment.ConclusionsTIS21/BTG2 significantly lost in the infiltrating ductal carcinoma, but it can inhibit cancer growth via the TIS21/BTG2–tsc1/2–mTORc1–p70S6K axis and downregulate cancer progression via the TIS21/BTG2–mTORc2–AKT1–NFAT1–PHLPP2 pathway.

[1]  Tatsuro Watanabe,et al.  Inhibition of TNFα-interacting protein α (Tipα)-associated gastric carcinogenesis by BTG2/TIS21 via downregulating cytoplasmic nucleolin expression , 2018, Experimental & Molecular Medicine.

[2]  M. Ellis,et al.  A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[3]  R. Berger,et al.  Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway , 1996, Nature Genetics.

[4]  B. Séraphin,et al.  BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation , 2016, Nature Communications.

[5]  Nipun A. Mistry,et al.  p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer , 2016, Breast Cancer Research.

[6]  Xavier Messeguer,et al.  PROMO: detection of known transcription regulatory elements using species-tailored searches , 2002, Bioinform..

[7]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[8]  B. Hemmings,et al.  Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase*♦ , 2004, Journal of Biological Chemistry.

[9]  D. Guardavaccaro,et al.  Arrest of G1-S Progression by the p53-Inducible Gene PC3 Is Rb Dependent and Relies on the Inhibition of Cyclin D1 Transcription , 2000, Molecular and Cellular Biology.

[10]  G. Getz,et al.  DNA microarrays identification of primary and secondary target genes regulated by p53 , 2001, Oncogene.

[11]  I. Lim,et al.  B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFκB pathways which enhances transcription of MnSOD by accelerating IκBα degradation in normal and cancer cells , 2013, Cell Communication and Signaling.

[12]  Wun-Jae Kim,et al.  Inhibition of bladder cancer invasion by Sp1‐mediated BTG2 expression via inhibition of DNA methyltransferase 1 , 2014, The FEBS journal.

[13]  M. Ciotti,et al.  Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro‐differentiative gene PC3 , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[15]  A. Toker,et al.  AKT/PKB Signaling: Navigating the Network , 2017, Cell.

[16]  G. Merlino,et al.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation , 2018, Oncogene.

[17]  M. Simons,et al.  Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Cα in endothelial cells , 2004 .

[18]  E. Giovannetti,et al.  Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression , 2015, The Lancet.

[19]  Michael L. Wang,et al.  Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma , 2014, British journal of haematology.

[20]  J. Testa,et al.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.

[21]  K. Inoki,et al.  Monitoring mammalian target of rapamycin (mTOR) activity. , 2009, Methods in enzymology.

[22]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[23]  H. Wang,et al.  TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1–Forkhead box M1 regulation loop , 2008, Hepatology.

[24]  M. Simons,et al.  Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. , 2004, Cellular signalling.

[25]  Wenbin Zhou,et al.  MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2 , 2018, Molecular Cancer.

[26]  Holger Moch,et al.  Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma , 2004, Cancer Research.

[27]  Jong-Wook Hong,et al.  TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. , 2004, Experimental cell research.

[28]  Ben S. Wittner,et al.  Supplementary Information Supplementary Figures , 2022 .

[29]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[30]  I. Lim,et al.  Inhibition of breast cancer invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes , 2016, Oncogene.

[31]  I. Lim,et al.  TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells , 2013, Journal of Cancer Research and Clinical Oncology.

[32]  B. Karlan,et al.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. , 2003, Cancer research.

[33]  Min Liu,et al.  Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma , 2009, Cell Research.

[34]  J. Melamed,et al.  Expression of B-cell translocation gene 2 protein in normal human tissues. , 2002, Tissue & cell.

[35]  S. Naber,et al.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. , 2007, Cancer research.

[36]  A. Toker,et al.  NFAT proteins: emerging roles in cancer progression , 2009, Nature Reviews Cancer.

[37]  J. Downward,et al.  Rictor is a novel target of p70 S6 kinase-1 , 2010, Oncogene.

[38]  A. Toker,et al.  Akt/Protein Kinase B and Glycogen Synthase Kinase-3β Signaling Pathway Regulates Cell Migration through the NFAT1 Transcription Factor , 2009, Molecular Cancer Research.

[39]  S. Matsuda,et al.  In search of a function for the TIS21/PC3/BTG1/TOB family , 2001, FEBS letters.

[40]  S. Maheswaran,et al.  Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. , 2006, Cancer research.

[41]  Andrew H. Beck,et al.  NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer , 2015, Molecular oncology.

[42]  S. Ramaswamy,et al.  Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib , 2011, Oncogene.

[43]  T. Park,et al.  Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin‐dependent kinase 4 proteins due to overexpression of TIS21 , 1998, Molecular carcinogenesis.

[44]  S. P. Oh,et al.  TIS21/BTG2 Negatively Regulates Estradiol‐Stimulated Expansion of Hematopoietic Stem Cells by Derepressing Akt Phosphorylation and Inhibiting mTOR Signal Transduction , 2008, Stem cells.

[45]  G. Watkins,et al.  Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. , 2005, European journal of cancer.

[46]  N. Kim,et al.  Experimental Oncology Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines , 2005, Journal of Cancer Research and Clinical Oncology.

[47]  M. Rubin,et al.  Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis. , 2001, Carcinogenesis.

[48]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[49]  S. Maheswaran,et al.  Expression of the NF-κB-responsive gene BTG2 is aberrantly regulated in breast cancer , 2004, Oncogene.

[50]  S. Dedhar,et al.  Regulation of Protein Kinase B/Akt-Serine 473 Phosphorylation by Integrin-linked Kinase , 2001, The Journal of Biological Chemistry.